Valeant Pharmaceuticals Intl (VRX) Stock Rating Lowered by TD Securities

TD Securities cut shares of Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) from a buy rating to a hold rating in a research note published on Friday morning, Marketbeat.com reports. The brokerage currently has $24.00 target price on the specialty pharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Cantor Fitzgerald set a $25.00 price objective on Valeant Pharmaceuticals Intl and gave the stock a buy rating in a research note on Wednesday, February 28th. Deutsche Bank raised Valeant Pharmaceuticals Intl from a hold rating to a buy rating and set a $18.00 price target for the company in a research report on Monday, March 5th. Jefferies Financial Group increased their price target on Valeant Pharmaceuticals Intl to $23.00 and gave the company a buy rating in a research report on Wednesday, May 9th. Mizuho raised Valeant Pharmaceuticals Intl from a neutral rating to a buy rating in a research report on Tuesday, May 15th. Finally, TheStreet downgraded Valeant Pharmaceuticals Intl from a c rating to a d+ rating in a research report on Friday, May 25th. Five equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $20.54.

Get Valeant Pharmaceuticals Intl alerts:

Shares of Valeant Pharmaceuticals Intl opened at $24.27 on Friday, Marketbeat.com reports. The company has a market capitalization of $8.63 billion, a PE ratio of 6.34, a P/E/G ratio of 0.37 and a beta of -0.34. Valeant Pharmaceuticals Intl has a 52 week low of $10.94 and a 52 week high of $27.79. The company has a debt-to-equity ratio of 5.59, a current ratio of 1.18 and a quick ratio of 0.92.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.60 by $0.29. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.95 billion. Valeant Pharmaceuticals Intl had a positive return on equity of 27.87% and a negative net margin of 10.65%. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.79 earnings per share. equities research analysts predict that Valeant Pharmaceuticals Intl will post 3.33 earnings per share for the current fiscal year.

In other news, Director Schutter Richard U. De acquired 15,000 shares of Valeant Pharmaceuticals Intl stock in a transaction on Tuesday, May 15th. The stock was acquired at an average cost of $21.83 per share, with a total value of $327,450.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.87% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. First Allied Advisory Services Inc. boosted its holdings in shares of Valeant Pharmaceuticals Intl by 33.6% in the first quarter. First Allied Advisory Services Inc. now owns 15,101 shares of the specialty pharmaceutical company’s stock worth $242,000 after acquiring an additional 3,800 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Valeant Pharmaceuticals Intl by 189.4% in the first quarter. Envestnet Asset Management Inc. now owns 5,991 shares of the specialty pharmaceutical company’s stock worth $103,000 after acquiring an additional 3,921 shares during the period. Gabelli Funds LLC boosted its holdings in shares of Valeant Pharmaceuticals Intl by 3.5% in the first quarter. Gabelli Funds LLC now owns 117,088 shares of the specialty pharmaceutical company’s stock worth $1,864,000 after acquiring an additional 4,000 shares during the period. MML Investors Services LLC boosted its holdings in shares of Valeant Pharmaceuticals Intl by 15.5% in the fourth quarter. MML Investors Services LLC now owns 40,581 shares of the specialty pharmaceutical company’s stock worth $843,000 after acquiring an additional 5,431 shares during the period. Finally, Prime Capital Investment Advisors LLC bought a new position in shares of Valeant Pharmaceuticals Intl in the fourth quarter worth $142,000. 46.95% of the stock is owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)